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ABSTRACT
Peripheral neuropathy is a disorder of the peripheral nerves and results from a disturbance of structure and/or function of the 
peripheral sensory, motor and/or autonomic neurons. The possible aetiology of peripheral neuropathies is diverse, but inflam-
matory and hereditary diseases of the peripheral nerves predominate in childhood. The aim of this study was to determine the 
clinical and electrophysiological profile of large nerve fibre neuropathy detected by nerve conduction studies (NCS) in children 
over a 10-year period at the Children’s Clinical University Hospital in Latvia. Based on NCS findings, 165 children between 
2008 and 2018 were diagnosed with polyneuropathy. In our study, the majority of children had peripheral neuropathy due to 
acquired causes, mostly due to diabetes mellitus; roughly one in five of the patients had hereditary neuropathy. Almost half of 
the patients had motor deficits, which were more prevalent in toxic and inflammatory neuropathies. A little less than a third 
of patients complained of pain as well as presenting with autonomic dysfunction symptoms. The NCS demonstrated a demy-
elinating neuropathy in 52 cases (31%), an axonal neuropathy in 34 cases (21%), and mixed polyneuropathy in 79 cases (48%). 
Our study investigated the clinical and electrophysiological characteristics of polyneuropathies diagnosed with NCS in children. 
Most of the polyneuropathies in our study were hereditary and diabetic neuropathies with combined (myelin and axon) damage 
to nerve fibres. Almost all clinical symptoms of polyneuropathy were present in all aetiological groups.
Key words: polyneuropathy, childhood, clinical, neurophysiology
(Neurol Neurochir Pol 2020; 54 (5): 466–470)
Introduction
Peripheral neuropathy is a disorder of the peripheral nerves 
and results from a disturbance of structure and/or function 
of the peripheral sensory, motor and/or autonomic neurons. 
Typically, the involvement of motor fibres can cause weakness, 
fasciculations, or muscle atrophy, whereas sensory involvement 
causes numbness, tingling, and/or altered perception of pain [1].
The possible aetiology of peripheral neuropathies is 
diverse and includes infection, autoimmune, neoplasmatic, 
endocrine, metabolic, congenital and toxic disorders. Among 
adult patients, metabolic polyneuropathies are the most fre-
quent. However, inflammatory and hereditary diseases of the 
peripheral nerves predominate in childhood [1, 2]. 
The aim of this study was to determine the clinical and 
electrophysiological profile of large nerve fibere neuropathy 
detected by nerve conduction studies (NCS) in children over 




Study participants were enrolled in a tertiary hospital 
in Riga, Latvia. The study included children (i.e. under 
the age of 18 years) with polyneuropathy confirmed by 
NCS at the Children’s Clinical University Hospital from 
2008 to 2018. 
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Clinical and neurophysiological examination
Medical history anamnesis, clinical and laboratory data 
were gathered from the patients’ medical records. We retro-
spectively studied the results of all nerve conduction studies 
(NCS) performed between 2008 and 2018. NCS were per-
formed in the sural nerve and at least one other motor nerve 
in each leg, and in two sensory nerves and one motor nerve 
in each hand. Two trained neurophysiologists independently 
re-evaluated the data from all nerve conduction studies.
The summarised data was broken down into groups based 
on clinical presentation or aetiology as having either hered-
itary or acquired causes. Acquired causes were categorised 
into being either diabetic, toxic, autoimmune, or neuropathy 
due to other cause.
Ethics
This study was approved by the the Ethics Committees of 
the Children’s Clinical University Hospital and of Riga Stradins 
University (No. 4/22.02.2018).
Results
Based on NCS findings, 165 children between 2008 and 
2018 were diagnosed with polyneuropathy. There was a slight 
male predominance: 55.8% (n = 92) males and 44.2% (n = 73) 
females. Patients were aged from one month to 17 years. The 
mean age was 12.25 ± 5.10 years. 
The majority of children had peripheral neuropathy due 
to acquired causes (Tab. 1), mostly due to diabetes mellitus, 
followed by toxic causes. Almost all children with toxic pol-
yneuropathy had been treated with chemotherapy. However, 
about one fifth of the patients had an inherited cause of periph-
eral neuropathy, and 64% (n = 23) of them had Charcot Marie 
Tooth subtype 1A. However, in 15% the cause of neuropathy 
was idiopathic. Inflammatory neuropathy patients had Guil-
lain-Barre syndrome or chronic inflammatory polyneuropa-
thy. Neuropathy due to other causes was due to Prader-Willi 
syndrome, coeliac disease, Waardenburg syndrome, neurob-
orreliosis, hereditary spastic paraparesis, 3-methylglutaric 
aciduria, mitochondrial disease, rheumatic diseases, or liver 
cirrhosis. In the patient group aged younger than 17 years (n = 
112), the most prevalent cause for neuropathy was hereditary, 
followed by toxic causes.
Clinical features were summarised according to data from 
neurological examinations and medical records (Tab. 2). Al-
most half of the patients had motor deficits, which were more 
prevalent in toxic and inflammatory neuropathies. A little less 
than a third of patients complained of pain as well as presenting 
with autonomic dysfunction symptoms. In this group, the ma-
jority presented either toxic or diabetic causes of neuropathy. 
Sensory deficits were also more prevalent in toxic and diabetic 
neuropathies. Features of autonomic dysfunction included 
tachycardia (n = 22), gastrointestinal disturbances (n = 18), 
hypohidrosis (n = 6), hyperhidrosis (n = 4), and orthostatic 
hypotension (n = 3). Almost all clinically mentioned symptoms 
were present in all aetiological subgroups of polyneuropathy.
The NCS in our patient group (n = 165) demonstrated 
a demyelinating neuropathy in 52 cases (31%), an axonal 
neuropathy in 34 cases (21%), and mixed polyneuropathy 
in 79 cases (48%). Demyelinating neuropathy was defined 
when nerve conduction velocity was decreased and/or nerve 
distal latency was prolonged; axonal neuropathy was defined 
when action potential amplitude was decreased; and mixed 
neuropathy was defined when both demyelinating and axonal 
neuropathy features were present. 
A detailed NCS summary for a 126 patient group is set out 
in Table 3. Based on peripheral nervous system development 
and approximate maturation at 5–6 years [3], in NCS summary 
we excluded patients 0-6 years of age (n = 30) and patients with 
neuropathy due to another disease (n = 11, two of them aged 
under six). In the patient group 0-6 years (n = 30), NCS was 
evaluated individually according to age-specific NCS values 
and a diagnosis of neuropathy was made. Although patients 
with hereditary neuropathies can present with various NCS 
findings, our data showed prolonged latency with decreased 
conduction velocity, indicating the demyelination of peripheral 
nerves. The amplitude of the action potential was generally 
preserved. In cases of inflammatory neuropathy, patients 
tended to have similar findings as the hereditary neuropathy 
group, but with less severely expressed signs of demyelination. 
Table 1.  Aetiological spectrum of polyneuropathies
Aetiology Number of patients (%) Number of patients aged < 17 (%)
Hereditary cause 36 (21.8) 29 (25.9)
Acquired cause
Diabetic 40 (24.2) 9 (8.0)
Toxic 31 (18.8) 25 (22.3)
Autoimmune 22 (13.3) 20 (17.9)
Due to other disease 11 (6.7) 10 (8.9)
Idiopathic 25 (15.2) 19 (17.0)
Total 165 (100) 112 (100)
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Table 2.  Clinical features in polyneuropathies
Clinical feature Number of patients (%) Total number of patients (%)
Motor deficit 71 (48.0)
Hereditary 10 (14.1)
Inflammatory 16 (22.5)
Diabetic   1 (1.4)
Toxic          21 (29.6)
Idiopathic 15 (21.1)




Diabetic   11 (23.4)
Toxic 15 (31.9)
Idiopathic 5 (10.6)
Due to other disease 2 (4.3)
Sensory deficit 26 (16.9)
Hereditary 2 (7.7)
Inflammatory 6 (23.1)
Diabetic   7 (26.9)
Toxic          8 (30.8)
Idiopathic 2 (7.7)
Due to other disease 1 (3.8)
Autonomic dysfunction 45 (30.4)
Hereditary 3 (6.7)
Inflammatory 5 (11.1)
Diabetic   16 (35.6)
Toxic          18 (40.0)
Idiopathic 0 (0)
Due to other disease 3 (6.7)
Patients with toxic and diabetic neuropathies tended to have 
mild large myelinated nerve fibre damage with signs of demy-
elination. More signs of axonal damage were evident in the 
group with idiopathic neuropathies. More severe neuropathy 
findings were seen in leg nerves compared to hand nerves 
during NCS.
Discussion
Hereditary causes have traditionally been considered the 
most common causes of neuropathy in children [2], but they 
were only the second commonest cause in our study.  The 
majority of children in our study had diabetic polyneuropathy. 
A possible bias affecting these results is the age distribution 
in our patient group: almost a third of our patients was aged 
17 years. However, in analysing patients younger than 17, 
the most prevalent cause for neuropathy was hereditary. The 
incidence of diabetes in childhood is increasing worldwide 
[4, 5], and NCS are used as a screening method for polyneu-
ropathy in patients with diabetes more commonly than in 
cases with other pathologies. However, we assume that the 
high prevalence in our study could also be associated with 
the socioeconomic conditions in Latvia that could have a neg-
ative impact on timely visits to the GP as well as the use of 
medications, treatment compliance, and regular blood sugar 
monitoring. Furthermore, an additional possible cause for this 
could be the long delay between the first complaint/symptom 
and the diagnosis of hereditary neuropathy.  According to our 
research, the mean time from first symptoms to diagnosis in 
the hereditary neuropathy group is 13.9 years (Millere et al., 
unpublished data). 
It should be noted that our study participants were pa-
tients with NCS-confirmed polyneuropathy, and that some 
of the aetiological groups may have been underrepresented. 
Clear anamnestic reasons plus clinical symptoms, for ex-
ample sensory deficits after chemotherapy or a genetically 
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confirmed and known hereditary neuropathy diagnosis in 
a family, are possible reasons for avoiding NCS. Therefore, 
toxic and hereditary polyneuropathies may be underrepre-
sented in our study. 
The patient with Prader-Willi syndrome was nine months 
old with diffuse hypotonia when NCS was performed and the 
diagnosis of sensory demyelinating polyneuropathy was made. 
Although there is little evidence for neuropathy in Prader-Willi 
syndrome, we included this patient in the ‘neuropathy due to 
other causes’ group. It is possible that there could be another 
metabolic or hereditary cause for neuropathy in this patient, 
who needs to be monitored in the future.
Motor and sensory deficit, pain and autonomic dysfunc-
tion were present in almost all aetiological groups of poly-
neuropathies. Sensory symptoms are often under-recognised, 
especially in younger children [6], and our data also shows 
a sensory symptom burden in only 16.9% of patients. Dia-
betic and toxic neuropathy symptoms with prevalent sensory 
deficits, pain and autonomic dysfunction correspond to small 
nerve fibre damage, although we did not perform quantitative 
sensory testing (QST). 
 Although we considered hereditary neuropathies as one 
group, hereditary neuropathies are very heterogenous in clin-
ical as well as NCS findings, either with more prevalent demy-
elination or axonal damage [7]. In Guillain-Barre syndrome, 
demyelination is the most prevalent neurophysiological 
finding [8], and our data also showed signs of demyelination 
in NCS.
Hereditary neuropathy complaints and early diagnosis is 
important for quality of life and early rehabilitation. For the 
most common hereditary neuropathy (Charcot Marie Tooth 
subtype 1A), therapy could be available soon [9]. In patients 
with diabetes, therapeutic efficacy and blood sugar control can 
be evaluated by neuropathy severity, and decisions on therapy 
corrections can be made accordingly.
Although NCS can be an unpleasant procedure for pa-
tients, it is a useful investigation to evaluate therapeutic success 
in diabetic neuropathy. It is a cheaper and faster method where 
genetic neuropathy is suspected compared to genetic testing. 
Conclusions
Our study investigated the clinical and electrophysiological 
characteristics of polyneuropathies diagnosed with NCS in 
children. Most of the polyneuropathies in the present study 
were hereditary and diabetic neuropathies with combined 
(myelin and axon) damage to nerve fibres. Patients with 
hereditary neuropathies tended to have more severe changes 
and signs of demyelination in NCS, followed by inflammato-
ry neuropathies, toxic and diabetic neuropathies. The latter 
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tended to have milder signs of peripheral nerve fibre damage. 
Almost all clinical symptoms of polyneuropathy were present 
in all aetiological groups. 
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